Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

First-in-human study explores use of NP-137 for advanced solid tumors

Jan. 16, 2017

Affimed provides update on NK-cell engager platform

Jan. 16, 2017

University of Connecticut and CaroGen collaborate on colon cancer vaccine

Jan. 16, 2017

Maverick and Takeda announce 5-year collaboration

Jan. 16, 2017

Phase I results from ZUMA-1 trial of KTE-C19 in patients with refractory DLBCL

Jan. 13, 2017

Takara Bio applies to conduct Japanese phase I/II study of CAR therapy

Jan. 13, 2017

Update on clinical trials of dendritic cell vaccine TLP0-001

Jan. 13, 2017

Amgen and Immatics Biotechnologies collaborate on novel bispecific cancer immunotherapies

Jan. 13, 2017

FDA accepts Adaptimmune's IND for T-cell therapy targeting MAGE-A4

Jan. 13, 2017

LegoChem and Takeda enter research licensing agreement to evaluate next-generation ADC candidates

Jan. 12, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...